AR104720A1 - Moduladores de ccr2 - Google Patents

Moduladores de ccr2

Info

Publication number
AR104720A1
AR104720A1 ARP160101482A ARP160101482A AR104720A1 AR 104720 A1 AR104720 A1 AR 104720A1 AR P160101482 A ARP160101482 A AR P160101482A AR P160101482 A ARP160101482 A AR P160101482A AR 104720 A1 AR104720 A1 AR 104720A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
cycloalkyl
heteroaryl
aryl
Prior art date
Application number
ARP160101482A
Other languages
English (en)
Inventor
Zhang Penglie
Zeng Yibin
Tanaka Hiroko
P Powers Jay
P Mmahon Jeffrey
Reddy Mali Venkat
M Lui Rebecca
Kalisiak Jaroslaw
Fan Junfa
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AR104720A1 publication Critical patent/AR104720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Compuestos que son moduladores del receptor de CCR2 y son útiles en composiciones farmacéuticas, métodos para el tratamiento de enfermedades y trastornos que involucran la activación patológica de receptores de CCR2. Reivindicación 1: Un compuesto caracterizado porque que tiene la fórmula (1); o una sal aceptable farmacéuticamente, hidrato, estereoisómero o rotámero del mismo; donde A es C(R⁵)(R⁶) o N(R⁵) los subíndices m y n son en forma independiente entre sí enteros de 0 a 2, y m + n es £ 3; R¹ se selecciona entre el grupo que consiste en arilo, aril-C₁₋₄ alquilo, heteroarilo y heteroaril-C₁₋₄ alquilo, donde la porción heteroarilo tiene entre 1 - 3 heteroátomos como miembros del anillo que se seleccionan entre N, O y S; y donde dichos grupos o porciones arilo y heteroarilo están sustituidos opcionalmente con entre 1 y 5 sustituyentes Rˣ; R² se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo, C₃₋₈ cicloalquilo, C₃₋₈ cicloalquil-C₁₋₄ alquilo, arilo, aril-C₁₋₄ alquilo, heteroarilo y heteroaril-C₁₋₄ alquilo, donde la porción heteroarilo tiene entre 1 - 3 heteroátomos como miembros del anillo que se seleccionan entre N, O y S; y donde dichos grupos o porciones arilo y heteroarilo están sustituidos opcionalmente con entre 1 y 4 sustituyentes Rˣ; u opcionalmente, R¹ y R² se combinan con el átomo de nitrógeno al cual cada uno está unido para formar un anillo monocíclico de 6 a 11 miembros o anillo fusionado bicíclico - heterocíclico o heteroarilo, donde el grupo -NR¹R² está además opcionalmente sustituido con entre 1 y 4 sustituyentes Rˣ; R³ se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo, C₃₋₈ cicloalquilo y C₃₋₈ cicloalquil-C₁₋₄ alquilo, cada uno de los cuales está opcionalmente sustituido con entre 1 - 3 sustituyentes Rʸ; R⁴ se selecciona entre el grupo que consiste en H, C₁₋₈ alquilo opcionalmente sustituido con 1 a 2 Rʸ, y -CO₂H; R⁵ se selecciona entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ alcoxi, C₃₋₈ cicloalquilo, C₃₋₈ cicloalquiloxi, C₃₋₈ cicloalquil-C₁₋₄ alquilo, C₁₋₈ alquilamino, di-C₁₋₈ alquilamino, arilo, ariloxi, arilamino, aril-C₁₋₄ alquilo, heteroarilo, heteroariloxi, heteroarilamino y heteroaril-C₁₋₄ alquilo, cada uno de los cuales está opcionalmente sustituido con entre 1 y 5 sustituyentes Rᶻ; R⁶ se selecciona entre el grupo que consiste en H, F, OH, C₁₋₈ alquilo y C₁₋₈ alcoxi, donde los grupos C₁₋₈ alquilo y C₁₋₈ alcoxi están sustituidos opcionalmente con entre 1 y 3 sustituyentes Rᶻ; u opcionalmente, R⁵ y R⁶ se unen para formar un anillo cicloalquilo espirocíclico de 5 ó 6 miembros que es opcionalmente insaturado, y tiene un grupo arilo fusionado que está opcionalmente sustituido con entre 1 y 4 sustituyentes Rᶻ; cada Rˣ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rᶜ, -CO₂Rᵃ, -CONRᵃRᵇ, -C(O)Rᵃ, -OC(O)NRᵃRᵇ, -NRᵇC(O)Rᵃ, -NRᵇC(O)₂Rᶜ, -NRᵃ-C(O)NRᵃRᵇ, NRᵃC(O)NRᵃRᵇ, -NRᵃRᵇ, -ORᵃ, -O-X¹-ORᵃ, -O-X¹-NRᵃRᵇ, -O-X¹-CO₂Rᵃ, -O-X¹-CONRᵃRᵇ, -X¹-ORᵃ, -X¹-NRᵃRᵇ, -X¹-CO₂Rᵃ, -X¹-CONRᵃRᵇ, -SF₅, -S(O)₂NRᵃRᵇ, y arilo o heteroarilo de 5 ó 6 miembros, donde cada X¹ es un C₁₋₄ alquileno; cada Rᵃ y Rᵇ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S, y opcionalmente sustituido con oxo; cada Rᶜ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; y opcionalmente cuando dos sustituyentes Rˣ están sobre átomos adyacentes, se combinan para formar un anillo carbocíclico fusionado de 5 ó 6 miembros, y donde los grupos arilo o heteroarilo están sustituidos opcionalmente con 1 - 3 miembros que se seleccionan entre halógeno, hidroxilo, C₁₋₄ alquilo, C₁₋₄ alcoxi, C₁₋₄ haloalquilo, y C₁₋₄ haloalcoxi; cada Rʸ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rᶠ, -CO₂Rᵈ, -CONRᵈRᵉ, -C(O)Rᵈ, -OC(O)NRᵈRᵉ, -NRᵉC(O)Rᵈ, -NRᵉC(O)₂Rᶠ, -NRᵈC(O)NRᵈRᵉ, -NRᵈC(O)NRᵈRᵉ, -NRᵈRᵉ, -ORᵈ, y -S(O)₂NRᵈRᵉ; donde cada Rᵈ y Rᵉ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S; cada Rᶠ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; cada Rᶻ se selecciona en forma independiente entre el grupo que consiste en halógeno, -CN, -Rⁱ, -CO₂Rᵍ, -CONRᵍRʰ, -C(O)Rᵍ, -OC(O)NRᵍRʰ, NRʰC(O)Rᵍ, -NRʰC(O)₂Rⁱ, -NRᵍC(O)NRᵍRʰ, -NRᵍRʰ-, -ORᵍ, -S(O)₂NRᵍRʰ, -X¹-Rʲ, -X¹-NRᵍRʰ, -X¹-CONRᵍRʰ, -X¹-NRʰC(O)Rᵍ, -NHRʲ, -NHCH₂Rʲ, y tetrazol; donde cada Rᵍ y Rʰ se selecciona en forma independiente entre hidrógeno, C₁₋₈ alquilo, C₃₋₆ cicloalquilo y C₁₋₈ haloalquilo, o cuando está unido al mismo átomo de nitrógeno se puede combinar con el átomo de nitrógeno para formar un anillo de 5 ó 6 miembros con entre 0 a 2 heteroátomos adicionales como miembros del anillo que se seleccionan entre N, O ó S y está opcionalmente sustituido con uno o dos oxo; cada Rⁱ se selecciona en forma independiente entre el grupo que consiste en C₁₋₈ alquilo, C₁₋₈ haloalquilo y C₃₋₆ cicloalquilo; y cada Rʲ se selecciona entre el grupo que consiste en C₃₋₆ cicloalquilo, pirrolinilo, piperidinilo, morfolinilo, tetrahidrofuranilo, y tetrahidropiranilo.
ARP160101482A 2015-05-21 2016-05-20 Moduladores de ccr2 AR104720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164957P 2015-05-21 2015-05-21

Publications (1)

Publication Number Publication Date
AR104720A1 true AR104720A1 (es) 2017-08-09

Family

ID=57320660

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101482A AR104720A1 (es) 2015-05-21 2016-05-20 Moduladores de ccr2

Country Status (27)

Country Link
US (4) US9783540B2 (es)
EP (1) EP3297438B1 (es)
JP (1) JP6841771B2 (es)
KR (1) KR102622891B1 (es)
CN (1) CN108135168B (es)
AR (1) AR104720A1 (es)
AU (1) AU2016263579B2 (es)
BR (1) BR112017024555A2 (es)
CA (1) CA2985194A1 (es)
CY (1) CY1124918T1 (es)
DK (1) DK3297438T3 (es)
ES (1) ES2904252T3 (es)
HR (1) HRP20220028T1 (es)
HU (1) HUE060376T2 (es)
IL (1) IL255509B (es)
LT (1) LT3297438T (es)
MA (1) MA42133A (es)
MX (1) MX2017014375A (es)
NZ (1) NZ737399A (es)
PL (1) PL3297438T3 (es)
PT (1) PT3297438T (es)
RS (1) RS62809B1 (es)
RU (1) RU2726206C2 (es)
SI (1) SI3297438T1 (es)
TW (1) TWI733670B (es)
WO (1) WO2016187393A1 (es)
ZA (1) ZA201707966B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046025B2 (en) 2013-06-07 2015-06-02 GM Global Technology Operations LLC Selective catalytic reduction device monitoring system
WO2016187393A1 (en) * 2015-05-21 2016-11-24 Chemocentryx, Inc. Ccr2 modulators
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
US20200138921A1 (en) * 2017-06-23 2020-05-07 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
WO2019060820A1 (en) * 2017-09-25 2019-03-28 Chemocentryx, Inc. POLYTHERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR
AU2018347361A1 (en) 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
MA50423A (fr) * 2018-01-08 2020-08-26 Chemocentryx Inc Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
JP7263659B2 (ja) * 2018-02-02 2023-04-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
US20220204608A1 (en) 2019-04-17 2022-06-30 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
CN112773805A (zh) * 2019-11-11 2021-05-11 中国科学院脑科学与智能技术卓越创新中心 缺血性脑损伤的新型治疗药物
CN111139294A (zh) * 2020-01-06 2020-05-12 中国药科大学 Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用
CN111423454B (zh) * 2020-04-24 2021-06-22 苏州大学 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012712A (es) 2000-06-30 2003-04-25 Bristol Myers Squibb Pharma Co N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
WO2002013824A1 (en) 2000-08-17 2002-02-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
DK1501507T3 (da) * 2002-04-29 2008-09-29 Merck & Co Inc Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
TWI262077B (en) * 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
ATE404538T1 (de) 2002-04-29 2008-08-15 Merck & Co Inc Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität
US20060030582A1 (en) 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AU2003284975B2 (en) 2002-10-30 2009-04-02 Merck Sharp & Dohme Corp. Heteroarylpiperidine modulators of chemokine receptor activity
EP1599206A4 (en) 2003-02-24 2008-05-21 Merck & Co Inc MODULATORS OF HETEROTRICYLICAMIDE FUSIONED WITH AMINOCYCLOPENTYL OF ACTIVITY OF CHEMOKINE RECEPTORS
WO2004082682A1 (en) 2003-03-18 2004-09-30 Merck & Co. Inc. Amino cyclobutylamide modulators of chemokine receptor activity
RU2301802C2 (ru) * 2003-04-15 2007-06-27 Мерк Энд Ко., Инк. Бензоксазинил-амидоциклопентил-гетероциклические модуляторы хемокиновых рецепторов
CA2521625A1 (en) 2003-04-17 2004-11-04 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
BRPI0415836A (pt) 2003-10-27 2007-01-02 Merck & Co Inc composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
WO2005067502A2 (en) * 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
CA2555073A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Amino heterocyclic modulators of chemokine receptor activity
EP1746997A4 (en) 2004-05-11 2010-12-29 Incyte Corp 3- (4-HETEROARYLCYCLOHEXYLAMINE) CYCLOPENTANCARBOXAMIDE AS MODULATORS OF CHEMOKIN RECEPTORS
PA8653301A1 (es) 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
US20080194548A1 (en) 2005-01-06 2008-08-14 Forrest Michael J Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
CN100364643C (zh) * 2006-05-11 2008-01-30 同济大学 一种从排气中吸附回收净化有机物的方法和装置
US7671062B2 (en) * 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
EA018997B1 (ru) 2008-12-10 2013-12-30 Янссен Фармацевтика Нв Антагонисты ccr2 группы 4-азетидинил-1-гетероарилциклогексанола
JP5685580B2 (ja) 2009-04-16 2015-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ Ｃｃｒ２の４−アゼチジニル−１−ヘテロアリール−シクロヘキサンアンタゴニスト
WO2010121046A1 (en) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
JP5632014B2 (ja) * 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用
EP2534158B1 (en) 2010-02-09 2014-01-08 Bristol-Myers Squibb Company Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
SG193002A1 (en) * 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
WO2016187393A1 (en) * 2015-05-21 2016-11-24 Chemocentryx, Inc. Ccr2 modulators

Also Published As

Publication number Publication date
CN108135168A (zh) 2018-06-08
LT3297438T (lt) 2022-01-25
HUE060376T2 (hu) 2023-02-28
RS62809B1 (sr) 2022-02-28
MA42133A (fr) 2021-06-02
US20160340356A1 (en) 2016-11-24
RU2017144651A3 (es) 2019-11-06
US9783540B2 (en) 2017-10-10
ES2904252T3 (es) 2022-04-04
US20180086756A1 (en) 2018-03-29
CY1124918T1 (el) 2023-01-05
AU2016263579A1 (en) 2017-12-07
SI3297438T1 (sl) 2022-03-31
KR20180103683A (ko) 2018-09-19
CA2985194A1 (en) 2016-11-24
US10464934B2 (en) 2019-11-05
RU2726206C2 (ru) 2020-07-09
NZ737399A (en) 2023-01-27
EP3297438A1 (en) 2018-03-28
AU2016263579B2 (en) 2020-12-03
TWI733670B (zh) 2021-07-21
EP3297438B1 (en) 2021-10-20
BR112017024555A2 (pt) 2018-07-24
JP6841771B2 (ja) 2021-03-10
JP2018515553A (ja) 2018-06-14
RU2017144651A (ru) 2019-06-24
DK3297438T3 (da) 2022-01-17
CN108135168B (zh) 2021-07-20
PT3297438T (pt) 2022-01-25
ZA201707966B (en) 2021-04-28
US20220153733A1 (en) 2022-05-19
US20200121688A1 (en) 2020-04-23
TW201706266A (zh) 2017-02-16
KR102622891B1 (ko) 2024-01-08
PL3297438T3 (pl) 2022-02-21
MX2017014375A (es) 2018-06-20
HRP20220028T1 (hr) 2022-04-01
IL255509B (en) 2021-04-29
EP3297438A4 (en) 2018-12-05
IL255509A (en) 2018-01-31
WO2016187393A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
AR104720A1 (es) Moduladores de ccr2
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR103252A1 (es) Compuestos de quinazolina
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR112834A1 (es) Derivados de rapamicina
AR108207A1 (es) Derivados de pirrolo[2,3-c]piridina, inhibidores de bromodominios
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR099789A1 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR107955A1 (es) Derivados de piridino- / pirimidino-piridina, con actividad herbicida
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos
AR104539A1 (es) Compuestos cíclicos
AR096552A1 (es) Compuesto de amida heterocíclica aromática que contiene nitrógeno bicíclico